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Background: In Australia, cancer survival is significantly lower in non-metropolitan com-
pared to metropolitan areas. Our objective was to evaluate the evidence on geographical 
variations in the clinical management and treatment of colorectal cancer (CRC).
methods: A systematic review of published and gray literature was conducted. Five 
databases (CINAHL, PubMed, Embase, ProQuest, and Informit) were searched for 
articles published in English from 1990 to 2018. Studies were included if they assessed 
differences in clinical management according to geographical location; focused on CRC 
patients; and were conducted in Australia. Included studies were critically appraised 
using a modified Newcastle–Ottawa Scale. PRISMA systematic review reporting meth-
ods were applied.
Results: 17 articles met inclusion criteria. All were of high (53%) or moderate (47%) 
quality. The evidence available may suggest that patients in non-metropolitan areas are 
more likely to experience delays in surgery and are less likely to receive chemotherapy 
for stage III colon cancer and adjuvant radiotherapy for rectal cancer.
conclusion: The present review found limited information on clinical management 
across geographic regions in Australia and the synthesis highlights significant issues 
both for data collection and reporting at the population level, and for future research in 
the area of geographic variation. Where geographical disparities exist, these may be due 
to a combination of patient and system factors reflective of location. It is recommended 
that population-level data regarding clinical management of CRC be routinely collected 
to better understand geographical variations and inform future guidelines and policy.
Keywords: colorectal cancer, rural health, health disparity, cancer treatment, systematic review
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iNtRODUctiON
Australia and New Zealand have the highest incidence rates of 
colorectal cancer (CRC) in the world, and it is the second leading 
cause of cancer death in Australia (1, 2). Around 80 Australians 
die each week from CRC; however, if detected early it can be 
treated successfully (3). The Australian National Health and 
Medical Research Council and Cancer Australia have developed 
evidence-based guidelines for optimal care in the clinical man-
agement of CRC (4, 5). These guidelines recommend that patients 
should receive site- and stage-specific care including preoperative 
assessment, surgery, and adjuvant therapy where appropriate. 
Specifically, primary surgical resection is recommended for stage 
I to III CRC, except for low-grade stage I where local excision is 
appropriate; adjuvant chemotherapy for all node-positive colon 
cancers; adjuvant preoperative or postoperative radiotherapy 
for high risk rectal cancers; and chemotherapy for metastatic 
CRC. The guidelines also recommend less than 30 days between 
diagnosis and surgery, and receipt of treatment in specialist 
cancer centers or from specialist surgeons (5). To date, it is 
unclear whether these guidelines are adhered to uniformly across 
Australia.
In Australia, survival from CRC differs according to geo-
graphical location, with mortality rates higher in regional and 
remote areas compared to major cities (1, 6–8). Geographical 
variations in access to recommended treatments may contribute 
to the noted disparities in survival and other outcomes. Only 78 
sites across Australia deliver radiotherapy treatment (42% private 
providers), with the majority of these located in capital cities or 
major regional centers (9). An analysis of available radiotherapy 
services in Australia in 2009 found that only 38% of cancer patients 
for whom radiotherapy was the appropriate treatment could be 
treated within the current service capacity, with lower percent-
ages expected in regional and rural Australia (10). Geographical 
differences in surgery and chemotherapy also exist as there are 
reported gaps in the percentage of non-metropolitan hospitals 
with medical oncologists or specialist surgeons, and reports of 
administration of chemotherapy by staff without oncology train-
ing (11, 12).
Residents in metropolitan areas have increased access to ser-
vices, and access to hospitals and surgeons with higher caseloads; 
factors known to be associated with better clinical outcomes (13, 
14). However, few population-level datasets in Australia include 
comprehensive treatment data or clinical management informa-
tion (15), and to date, there has been no aggregation and synthesis 
of available data. This evidence gap hampers our understanding 
of disparities in clinical care and how these might influence can-
cer outcomes. A preliminary survey of the literature regarding 
geographic disparities in outcomes for patients diagnosed with 
CRC highlighted a lack of clear, consistent findings and identified 
a need for a more in-depth examination of differences in clinical 
management (8). Thus, the primary aim of this systematic review 
was to understand the nature of geographical variations in the 
clinical management of CRC (including surgery, chemotherapy, 
and radiotherapy) in Australia, incorporating clinical reports as 
well as peer-reviewed literature.
metHODS
The review methodology was planned and carried out follow-
ing the PRISMA statement for the conduct and reporting of 
systematic reviews (16). The review protocol was registered 
with PROSPERO; registration number CRD42016042666 
(https://www.crd.york.ac.uk/PROSPERO/display_record.
asp?ID=CRD42016042666).
eligibility criteria
Studies were included if the data were from cohorts of 
Australian individuals with CRC; reflected outcomes pertain-
ing to clinical management; and compared non-metropolitan 
vs metropolitan patients. Qualitative studies, review articles, 
editorials, books, commentaries, and conference abstracts were 
excluded.
Search Strategy
PubMed, CINAHL, Embase, ProQuest, and Informit databases 
were searched for articles published in English from 1990 to 
26th February 2018. Search strings included terms relating to 
“colorectal cancer” or “bowel cancer,” “clinical management,” 
“treatment,” “chemotherapy,” “radiotherapy,” or “surgery.” Terms 
relating to geographical disparities included “metropolitan,” 
“urban,” “rural,” “remote” or “regional,” and “Australia.”
Gray literature searches were conducted through targeted 
Internet searches of state and federal government health websites, 
non-government cancer association (e.g., state Cancer Council 
groups) websites, web search engines (Google), and manual hand 
searching of reference lists of included articles.
Screening and Data extraction
After removing duplicates, titles and abstracts were indepen-
dently screened by two reviewers for relevance according to the 
selection criteria. Full text versions of potentially eligible articles 
were then assessed for inclusion by two independent reviewers. 
Reviewer discrepancies were discussed and resolved within the 
project team where necessary.
Criteria for data extraction were determined prior to review. 
Summary data for each study included design, data sources, 
participants, geographic classification system, dates of data col-
lection, clinical management details, and key trends. Extracted 
data were synthesized descriptively.
Quality assessment
The methodological quality of each paper meeting the inclu-
sion criteria was assessed using a tool previously developed for 
research in breast cancer, based on the Newcastle–Ottawa Scale 
for assessing quality in non-randomized studies (17, 18). Studies 
were scored according to the extent that they met each of nine 
criteria ranging from high risk of bias (score of 0), intermediate 
risk of bias (score of 1), and low risk of bias (score of 2). Criteria 
scores were then summed and categorized as “high” (14–18), 
“moderate” (9–13), or “low” (<9) quality. Study quality appraisal 
was carried out by two authors, and a third author resolved disa-
greements between the initial two reviewing authors.
FiGURe 1 | PRISMA flow diagram of included studies.
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ReSULtS
The search strategy yielded 690 records in total. After removal 
of duplicates, 681 records were screened by title and abstract. Of 
those, 153 full-text articles were potentially relevant and assessed 
for eligibility. Following assessment, 17 studies were included in 
the final review, comprising 12 peer-reviewed articles and 5 gray 
literature reports (Figure 1). Because of the diverse nature of the 
study designs, a quantitative synthesis was not possible and a 
narrative review of individual studies is provided.
Table 1 presents the key characteristics of all 17 included stud-
ies. Eight studies (47%) were of moderate quality, including all 
five gray literature reports. All other included studies (53%) were 
high quality indicating they have samples that were representa-
tive of the population, variables were collected through secure 
records, important confounders were controlled for, and statisti-
cal methods were appropriate and well presented.
main Findings
Surgery
Eight studies reported on surgical management. Three studies 
reported no significant variation in rates of surgical treatment 
according to place of residence, for all stage cancers (15) or 
metastatic disease (27, 32). Five studies reported geographical 
variations in aspects of surgical management, although method-
ologies varied greatly. A retrospective data linkage study found 
that patients residing in remote areas of Western Australia were 
more likely to receive surgery compared to patients residing in 
any other area (25). However, when location of hospital was 
considered, patients were more likely to receive surgery when 
their first admission was to a metropolitan facility rather than 
a rural hospital (25, 28). A Queensland audit report suggested 
that it was more likely for patients residing in metropolitan areas 
to have surgery less than 30  days after diagnosis, compared to 
patients in outer regional and remote areas (31). A retrospective 
cohort analysis from New South Wales reported that among 
rectal cancer patients there was a longer delay until surgery for 
individuals living in rural areas, but this was not the case for colon 
cancer patients (24). A clinicians report from NSW examined 
preoperative investigations, and reported that patients residing 
in highly accessible areas were significantly more likely to have 
had recommended tests such as colonoscopy, sigmoidoscopy, 
and scans for distant metastases compared to those living in less 
accessible areas (13).
Chemotherapy
Eight studies examined chemotherapy management. Three stud-
ies indicated that chemotherapy for stage III colon cancer was less 
ta
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likely to be received by patients residing in rural and remote areas 
than metropolitan areas (15, 19, 33). One study found equivalent 
rates of chemotherapy management between patients residing 
in metropolitan and rural areas across each line of treatment, 
although higher proportions of metropolitan patients received 
combination chemotherapy in the first-line, and rural patients 
had increased use of the oral prodrug capecitabine as first-line 
treatment compared to metropolitan patients (27). In contrast, 
two Queensland studies reported a similar number of chemo-
therapy cycles, regimen types, and dose-intensities used in both 
rural and urban areas (22, 30). Two retrospective cohort studies 
reported no geographical variation in receipt of chemotherapy 
(28, 29).
Radiotherapy
Five studies examined radiotherapy management in rectal 
cancer patients, with four reporting geographical disparities in 
radiotherapy use. Specifically, one retrospective cohort study 
reported lower utilization of radiotherapy in patients residing 
in rural Victoria that was not explained by age; a pattern that 
was more prominent in men than women (26). One cohort study 
conducted in New South Wales reported variability in receipt of 
radiotherapy as being attributable to location of hospital rather 
than place of residence, with radiotherapy less likely to occur in 
rural hospitals (28). In contrast, a New South Wales study of clini-
cian reports suggested that patients residing in highly accessible 
areas had lower use of radiotherapy than non-metropolitan areas; 
however, this study had small numbers of rectal cancer patients 
in moderately accessible and remote areas (20). One national 
cross-sectional study reported that patients residing in rural areas 
were less likely to receive preoperative radiotherapy for high-risk 
rectal cancer although it is unclear whether these patterns are 
indicative of patient characteristics, physician recommendations, 
or health service accessibility (23). Only one retrospective data-
linkage study found no differences in radiotherapy for stage II 
and stage III rectal cancer according to location of residence in 
South Australia (15).
DiScUSSiON
The current review found inconsistent evidence relating to geo-
graphical disparities in clinical management of CRC in Australia. 
While some studies showed no differences in treatment by loca-
tion of residence, other studies reported that patients with CRC 
in non-metropolitan areas of Australia are less likely to receive 
optimal care. This was particularly true for studies where the 
outcome was radiotherapy utilization. The evidence gathered in 
this review highlights key issues with consistency in current data 
collection and reporting regarding CRC treatments and clinical 
management. In particular, the review highlights the importance 
of recording location of treatment as well as location of residence; 
gaps in data collection at a population-level; and large variability 
in the methodologies used to investigate and report on geographi-
cal disparity. There is significant capacity for future research to 
focus on these critical issues, as well as aspects missing from the 
current literature such as treatment completion rates and reasons 
for non-receipt of adjuvant therapies.
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Population level data collected in cancer registries interna-
tionally provides information on all cancers occurring in a certain 
population (34). The type of data that cancer registries can provide 
is varied, and while most provide information on incidence and 
mortality, currently many registries, including those in Australia, 
do not routinely collect data on stage at diagnosis or treatment 
details (35). Hospital registries and other sources of clinical data 
may have this information available, but it is generally limited 
to a single institution or health service area. In clinical practice, 
factors such as position of the tumor, lymph node invasion, 
involved margins, as well as individual factors such as age, and 
comorbidities influence CRC treatment decisions (4, 36), yet, 
detailed clinical information is not available at the population 
level. This significantly hampers research efforts attempting to 
understand disparities in CRC management. The findings of the 
current review emphasize a need for more comprehensive data 
collection, particularly, in this era of electronic data. This might 
involve the use of standardized reporting database software such 
as electronic health records, whereby variables such as patients’ 
residence, hospital location, treatment type, tumor stage, and 
comorbidities are recorded and able to be linked to cancer regis-
try data. As the use of electronic health records and capacity for 
data-linkage expands in Australia, and worldwide, these provide 
a useful avenue for the collection of clinical management data 
for CRC patients, with the ability to share information across 
networks. The digital collection of cancer management data at 
the population level could result in complex databases to be used 
for a multitude of previously unanswered research questions (37).
Several studies reported that clinical management for CRC 
was less optimal in non-metropolitan areas of Australia. For 
instance, some studies reported that when non-metropolitan 
patients underwent surgery for CRC, it was more likely to be 
delayed and less likely to be preceded by preoperative investiga-
tions, radiotherapy for rectal cancer patients was underutilized 
in non-metropolitan areas, and non-metropolitan patients with 
stage III colon cancer were less likely to receive recommended 
chemotherapy treatment. Despite potential differences in the 
provision of chemotherapy across geographic locations, chemo-
therapy regimens were generally found to be similar across 
metropolitan and non-metropolitan areas (22, 30). However, 
one study indicated that oral chemotherapy was more likely 
to be used for rural patients with metastatic disease (27). The 
advantages of oral regimens over chemotherapy by infusion 
include convenience, flexibility in location of administration, 
and reduced toxicity-related hospitalization, which may be 
of benefit to patients in non-metropolitan areas (38–40). For 
these reasons, the use of innovative chemotherapy regimens is 
a promising solution for overcoming the barrier of distance for 
optimal CRC treatment.
Previous studies in Canada, the United States, and the United 
Kingdom have also reported less optimal treatment provided 
to non-metropolitan CRC patients (41–43), although again 
evidence is mixed (41). A number of international studies have 
reported that geographic variability in the treatment of CRC 
may be reflective of the different population compositions in 
regional areas, as well as hospital volume and service availability. 
For instance, older patients, black patients, and patients of lower 
socioeconomic status (SES) were less likely to receive recom-
mended treatments and more likely to have poorer outcomes 
(43–47). As rural Australia is also characterized by populations 
with lower education, lower SES, more advanced age, and higher 
rates of Indigenous populations (12, 48), these sociodemographic 
factors may explain many of the treatment differences reported 
in the current review. If SES, ethnicity, and demographic char-
acteristics are explanations for geographical disparity in cancer 
treatment resulting in poorer cancer outcomes, there is an issue 
of inequality that needs to be urgently addressed.
Studies that reported data comparing regional and metropoli-
tan facilities, rather than basing geographic location on patient’s 
home address, generally reported less optimal clinical manage-
ment in non-metropolitan areas. This may suggest that there 
are important differences in the quality of treatment for patients 
receiving treatment in regional areas. If disparities in clinical 
management of CRC are explained to some extent by accessibility 
to appropriate services, then changes to health service delivery 
may be an appropriate solution (11, 49). To date, increased use of 
telehealth, the development of approved oral chemotherapy regi-
mens, and the requirement for overseas trained health workers 
to work in rural and regional areas are strategies implemented to 
help overcome the challenge of distance (38, 50–52). The results 
of this review suggest that planning for health service delivery 
must continue to adapt and focus on overcoming barriers due 
to distance. In particular, high priority areas are the recruit-
ment and retention of specialist staff in non-metropolitan areas, 
reduction of wait times, and tailoring services to individuals of 
low SES, increased age, multiple comorbidities, and indigenous 
populations.
Based on evidence presented above, it appears that clinical 
management of CRC in non-metropolitan Australia may be less 
than optimal; however, this may be due to a range of patient and 
provider factors that correspond to geographic location. As evi-
dence in this area is limited, one major contribution of the current 
review is to motivate future research. Future studies will need to 
collect more detailed data on clinical indicators, health profes-
sionals decision-making, and patient preferences to shed light 
on potential variations in CRC treatment. To provide optimal 
treatment equitably to patients with CRC, a better understanding 
of the underlying causes of geographical variations in treatment 
is required. Digital data collection tools provide an opportunity to 
address this. Further investigation into the relative contribution 
of patient, provider, and health system factors to geographical 
disparities in clinical management is essential. Subsequently, 
interventions designed to improve the quality of care can then be 
directed at those patients most likely to benefit from them, such 
as the provision of extra care from nurse navigators by assessing 
and monitoring “at risk” patients. Additionally, health services 
can use this information to adapt appropriately to suit the needs 
of regional populations, for instance, through the extended use 
of tele-oncology models of care, oral chemotherapy regimens, or 
the development of outreach radiotherapy facilities to improve 
quality of care for those living outside city centers. Not only is 
this of relevance in Australia but also to countries with similar 
geographic distributions and population characteristics such as 
the US, Canada, and the UK.
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Limitations
This review is limited by the small number of studies and the 
use of inconsistent methodology across studies. The variation in 
population samples, and use of different geographical classifica-
tions made direct comparisons between studies difficult. Above 
all, research identifying geographical disparities in cancer out-
comes is hindered by the lack of accurate patient and treatment 
data at a population level. The use of digital systems to collect 
and record clinical management information would enhance 
understanding of variations in cancer outcomes and inform 
policy and clinical guidelines. The reviewed studies emphasize 
the need for better data collection and reporting, and highlight 
the need for the use of data linkage to gather comprehensive 
clinical management data.
conclusion
The present review provides specific information on clinical 
management differences across geographic regions in Australia. 
This synthesis of existing literature highlights significant issues 
both for data collection and reporting at the population level, an 
issue of relevance worldwide. Improvements in cancer outcomes 
in regional areas will require enhanced capacity to accurately 
track, and respond to, geographical disparities. Through the use 
of electronic health records, data linkage and future research, it 
is important to investigate differences in clinical management of 
CRC across geographical locations, and in particular, the patient, 
professional, or health service factors, which contribute to these 
disparities. Causes for disparities in treatment are found not only 
in the individual patients and their social environments but also 
in the location and quality of the health-care system. It is recom-
mended that population-level data regarding clinical manage-
ment of CRC is routinely collected to improve health outcomes 
and inform future guidelines and policy.
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